Levels of monoamine and amino acid neurotransmitters in the developing male mouse hypothalamus and in histotypic hypothalamic cultures

1998 ◽  
Vol 16 (5) ◽  
pp. 403-412 ◽  
Author(s):  
L. Miranda‐contreras ◽  
R.V. Mendoza‐Briceño ◽  
E.L. Palacios‐Prü
2021 ◽  
Vol 5 ◽  
pp. 247054702110204
Author(s):  
Julia Hecking ◽  
Pasha A. Davoudian ◽  
Samuel T. Wilkinson

Mood disorders represent a pressing public health issue and significant source of disability throughout the world. The classical monoamine hypothesis, while useful in developing improved understanding and clinical treatments, has not fully captured the complex nature underlying mood disorders. Despite these shortcomings, the monoamine hypothesis continues to dominate the conceptual framework when approaching mood disorders. However, recent advances in basic and clinical research have led to a greater appreciation for the role that amino acid neurotransmitters play in the pathophysiology of mood disorders and as potential targets for novel therapies. In this article we review progress of compounds that focus on these systems. We cover both glutamate-targeting drugs such as: esketamine, AVP-786, REL-1017, AXS-05, rapastinel (GLYX-13), AV-101, NRX-101; as well as GABA-targeting drugs such as: brexanolone (SAGE-547), ganaxolone, zuranolone (SAGE-217), and PRAX-114. We focus the review on phase-II and phase-III clinical trials and evaluate the extant data and progress of these compounds.


1992 ◽  
Vol 10 ◽  
pp. S39 ◽  
Author(s):  
John Chalmers ◽  
Leonard Arnolda ◽  
Vimal Kapoor ◽  
Ida Llewellyn-Smith ◽  
Jane Minson ◽  
...  

Tetrahedron ◽  
2007 ◽  
Vol 63 (41) ◽  
pp. 10133-10139 ◽  
Author(s):  
Maria J.G. Fernandes ◽  
M. Sameiro T. Gonçalves ◽  
Susana P.G. Costa

Sign in / Sign up

Export Citation Format

Share Document